Sign in
TerminatedPhase 3

Efficacy of Letrozole in Recurrent Ovarian Cancer

Key facts

Who runs it
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Where
Italy1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
Phase
Phase 3
People taking part
86 people enrolled
Started
22 Jun 2020
Ended
4 Nov 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Letrozole 2.5mg
  • Standard single agent chemotherapy
Record updated
7 March 2025
Why it stopped
Logistical problems impacting the speed of enrolment

Who can take part

Age
18 years and older
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 34 criteriaShow less

Who can take part

  • Female of 18 years of age or older
  • Histologically or cytologically documented invasive epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer
  • Platinum resistant or refractory disease (patients who did not respond to last platinumbased therapy or with last relapse occurred < 6 months from the last dose of platinum) or patients not amenable of platinum treatment
  • >3 previous chemotherapy lines
  • ECOG performance status 0 -2
  • Measurable and evaluable disease according to RECIST criteria confirmed by radiological imaging: at least one lesion of ≥ 1.0 cm for non-lymph nodes or ≥ 1.5 cm in short-axis diameter for lymph nodes at CT scan (Subjects with isolated rising CA-125 without radiologically visible disease are excluded)
  • Left Ventricular Ejection Fraction (LVEF) ≥ institutional lower limit normal
  • Estimated life expectancy ≥ 16 weeks
  • Adequate functions evidenced by:; Hemoglobin ³10.0 g/dl; Absolute neutrophil count ³1.5 x 109/L; White blood cells >3x109/L; Platelet >100 x109/L; AST and ALT £ 2.5 x Upper limit of normal, unless liver metastasis, in which case AST and ALT < or = 5 x Upper limit of normal will be accepted; Bilirubin ≤ 1.5 times the upper limit of normal (ULN); Estimated glomerular filtration ³ 60mL/min using the Cockcroft-Gault equation
  • Patient able to comply with the treatment
  • Evidence of not pregnancy status as documented by a negative beta-human chorionic gonadotropin (ß-hCG) test
  • Not breastfeeding women
  • Patients with child-bearing potential using (or willing to use) effective contraception during treatment and 3 months ahead unless they are postmenopausal (at least 12 months consecutive amenorrhea, in the appropriate age group and without other known or suspected cause), or have been sterilized surgically
  • Comprehension and signature of the informed consent

Who cannot take part

  • Less than 3 lines of previous therapies
  • Less than 4 weeks from last dose of therapy with any investigational agent, or chemotherapy
  • Prior therapy with letrozole
  • Prior resistance to Paclitaxel, PLD, Topotecan, Gemcitabine
  • Bowel obstruction, sub-occlusive disease, prior gastrectomy, symptomatic brain metastases
  • Myocardial infarct within six months before enrolment , NYHA Class II or worse heart failure, unstable angina, serious cardiac arrhythmia or cardiac arrhythmia requiring treatment
  • Any serious concomitant illness requiring treatment
  • Concomitant use of strong CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, voriconazole, ritonavir, clarithromycin, and telithromycin) or strong CYP2A6 inhibitors (e.g. methoxsalen) because they may increase exposure to letrozole
  • Concomitant use of inducers of CYP3A4 (e.g. phenytoin, rifampicin, carbamazepine, phenobarbital, and St. John's Wort) which may reduce exposure to letrozole
  • Subjects with borderline ovarian cancer
  • Subject with low malignant potential tumors
  • Platinum sensitive disease (last relapse occurred > 6 months from the last dose of platinum)
  • History of another neoplastic disease (except basal cell carcinoma or cervical carcinoma in situ adequately treated) unless in remission for 3 years or longer
  • Patients with active hepatic disease (HCV or HBV infections), hepatic severe impairment or cirrhosis
  • Patients with a known hypersensitivity to Paclitaxel , PLD, Topotecan, Gemcitabine or Letrozole or any case of severe toxicity related to them. Also Patients with a known hypersensitivity to any of the ingredients or excipients of the IMPs (e.g. macrogolglycerol ricinoleate (polyoxyl castor oil), ethanol, anhydrous, citric acid, anhydrous, sodium chloride hydrochloric acid, mannitol, sodium acetate, sodium hydroxide, tartaric acid, lactose monohydrate, maize starch, hypromellose Type 2910, cellulose microcrystalline, sodium starch glycolate type A, colloidal anhydrous silica, magnesium stearate, hypromellose 6 cp E464, titanium dioxide E171, Iron oxide yellow E172, Macrogol 400, talc E553b)
  • Concomitant use of medicinal products with a narrow therapeutic index that are substrates for CYP2C19 (e.g. phenytoin, clopidrogel) that may have their systemic serum concentrations altered by letrozole
  • Breastfeeding women
  • Pregnant women
  • Severe osteoporosis documented by BMD (Bone Mineral Density) T-score ≤ -2.5 with existing fragility fracture(s)
  • Pre-existing peripheral neuropathy > CTCAE Grade 2

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Randomized phase III multicenter study investigating the role of letrozole in heavily pretreated recurrent ovarian cancer.

The 2 groups in the trial

  • LetrozoleTreatment being tested

    Letrozole 1 tablet (2,5 mg) orally once a day

    Treatment: Letrozole 2.5mg

  • Standard ChemotherapyExisting treatment, for comparison

    Either Paclitaxel 80 mg/m2 as a 1-h infusion, on days 1,8,15,22 every 28 days or Pegylated Liposomal Doxorubicin (PLD) 40 mg/m2 given every 4 weeks or Topotecan 4mg/m2 IV on days 1,8,15 every 4 weeks or Gemcitabine 1000 mg/m2 IV over 30 min on days 1,8,15 every 28 days.

    Treatment: Standard single agent chemotherapy

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase III Randomized Control Case Study of Letrozole in Women With Heavily Pretreated Ovarian Cancer (MITO32)
Record updated
7 March 2025